Akeso, Inc.

9926.HK·HKSE·Healthcare

Compare

91.300+0.850 (+0.94%)today

At close: Oct 16, 4:08 PM HKT · May be delayed up to 15 min · HKD

Key statistics

Previous close90.450

Open92.150

Day range90.15095.300

52-week range80.200156.000

Off day high−4.20%

Off 52-week high−41.47%

Volume11.09M

Avg. volume (3M)10.97M

Market cap84.10B

EPS (TTM)-1.17

Forward P/E62.95

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)-0.03

Shares outstanding921.14M

Short interest—

Earnings dateAug 27, 2026

Analyst target153.997

Profit margin−28.03%

Against its peers

Compare in full ›

	9926.HK	GMAB	1177.HK	1801.HK	ONC	RCUS
Market cap	84.10B	23.70B	93.46B	155.29B	42.29B	2.73B
P/E (TTM)	—	30.3	35.0	117.2	66.5	—
Forward P/E	63.0	25.4	16.6	35.2	36.3	-6.9
Price/book	8.5	3.9	2.5	6.4	8.1	5.9
Dividend yield	—	—	2.67%	—	—	—
1-year change	−23.47%	+21.15%	−29.34%	+3.43%	+15.84%	+26.62%
Today	+0.94%	+4.16%	−0.38%	+1.48%	+0.73%	−1.90%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Related companies

Compare ›

The businesses closest to Akeso's by what they do, from their descriptions, with the same industry weighted in.

Company	Mkt cap	Price	Today
Genmab A/SGMAB · Biotechnology	23.70B	38.54	+4.16%
Sino Biopharmaceutical Limited1177.HK · Biotechnology	93.46B	5.250	−0.38%
Innovent Biologics, Inc.1801.HK · Biotechnology	155.29B	89.050	+1.48%
BeOne Medicines AGONC · Biotechnology	42.29B	371.74	+0.73%
Arcus Biosciences, Inc.RCUS · Biotechnology	2.73B	21.70	−1.90%
IDEAYA Biosciences, Inc.IDYA · Biotechnology	3.26B	33.83	+2.98%
Erasca, Inc.ERAS · Biotechnology	4.75B	13.58	+1.42%
Aktis Oncology, Inc.AKTS · Biotechnology	840.97M	15.12	+0.40%

The stocks whose daily moves over the past year went most closely with Akeso's: the correlation of their daily returns, where 1 would be moving as one.

Company	Mkt cap	Price	Today
INNOCARE9969.HK · Correlation 0.65	21.77B	12.320	+2.67%
Innovent Biologics, Inc.1801.HK · Correlation 0.64	155.29B	89.050	+1.48%
HANSOH PHARMA3692.HK · Correlation 0.53	192.43B	31.740	+1.15%
BeOne Medicines AG6160.HK · Correlation 0.51	332.77B	225.000	+4.36%
WUXI APPTEC2359.HK · Correlation 0.39	595.45B	196.200	−2.19%

What visitors to Akeso's page also look at.

Company	Mkt cap	Price	Today
INNOVENT BIO1801.HK	155.29B	89.050	+1.48%
BEONE MEDICINES6160.HK	332.77B	225.000	+4.36%
INNOCARE9969.HK	21.77B	12.320	+2.67%
HANSOH PHARMA3692.HK	192.43B	31.740	+1.15%
WUXI APPTEC2359.HK	595.45B	196.200	−2.19%

From the 4Search instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All 9926.HK news ›

BioPharma APAC·Oct 11Positive

Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer

BioPharma APAC - Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer 12 October 2026 | Monday | News Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a…

The Globe and Mail·Oct 10

Akeso, Inc. (9926) Receives a Hold from Bernstein

In a report released on October 8, Rebecca Liang from Bernstein maintained a Hold rating on Akeso, Inc., with a price target of HK$104.00. The company’s shares closed yesterday at HK$105.70. According to TipRanks, Liang is ranked #1393 out…

From articles in the 4Search news index.

In the news

2mentions in 30 days

2with it in the headline

Positivesentiment

Most coverage from

finance.biggo.com1
theglobeandmail.com1

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.

About

Profile ›

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody…

SectorHealthcare

IndustryBiotechnology

Chief executiveYu Xia Ph.D.

Employees4,082

HeadquartersZhongshan, China

Websiteakesobio.com

Analyst ratings

Analysis ›

Strong buy24 analysts

Strong buy 5
Buy 18
Hold 1
Sell 0
Strong sell 0

12-month price target153.997+68.67%

Low 104.282Current 91.300High 226.978

Wall Street analyst consensus. Not a recommendation.

Earnings

Reported EPS
Estimate

Next report: Thu, Aug 27, 2026

Quarterly results

Financials ›

Revenue
Net income

Prices may be delayed up to 15 min. Not investment advice.

Funds that hold it

KraneShares MSCI All China Health Care Index ETFKURE4.67%

Share of each fund, from the issuers' daily holdings files.

Track record

Leaderboard ›

Days on the list	30 d	1 yr	Best
Trending	0	0	—

Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).

Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).

Not eligible for Growth tech (U.S. technology stocks only).

Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).

A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.